ADIL
Azora Therapeutics, Inc. (DE)Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
Signal stack
Where each data set points today.
- InstitutionsBULLISH
Q3 2026: 4 added (0 new), 1 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$1.310 → −$2.575 over 90 days.
- Short sellersSTEADY
Short interest −2.0% to 179.6K shares. 4.5 days to cover, ≈6.8% of shares.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 29.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JANE STREET GROUP, LLC | ADD | $216.3K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $86.4K |
| VANGUARD FIDUCIARY TRUST CO | DOUBLED | $63.7K |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $41.7K |
| UBS Group AG | NEAR_EXIT | $6.8K |
| UBS Group AG | DOUBLED | $49.0K |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $31.7K |
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | $14.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2026| Date | Firm | Rating |
|---|---|---|
| Aug 3, 2026 | Alliance Global Partners INITIATE | Buy |
| Jun 15, 2026 | LUCID CAPITAL MARKETS INITIATE | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$2.58 | -$5.00–-$0.15 | +48.5% | $0.00 |
| Next Q | -$2.59 | -$5.00–-$0.18 | +48.2% | $0.00 |
| Current FY | -$1.05 | -$1.05–-$1.05 | No data | $0.00 |
| Next FY | -$7.45 | -$14.25–-$0.65 | +47.7% | $0.00 |
Short side
FINRA· Oct 15, 2026Washington
SecBot reports
18 filings · 5 press releases · 3 bullish · 6 bearish · 9 neutral- NEUTRAL PRESS-RELEASENov 12, 2026
Azora Therapeutics (formerly Adial Pharmaceuticals) reported a net loss of $64.6M for Q3 2026…
The company's cash runway of $22M is expected to fund operations through the IND and Phase 1a trial, but does not assume milestone warrant proceeds. Monitor for any milestone warrant exercises and…
- NEUTRAL 3Oct 30, 2026
Julie Saiki filed a Form 3 initial statement of beneficial ownership after becoming Chief Strategy…
Monitor for the actual conversion of Series A Preferred Stock into common shares, which will increase the outstanding share count. The conversion was approved on October 28, 2026 and should occur…
- NEUTRAL 3Oct 30, 2026
Vassiliki Economides filed a Form 3 initial statement of beneficial ownership upon becoming Chief…
New CFO onboarding is routine; monitor for future Form 4 filings that would indicate insider buying or selling activity.
- NEUTRAL 8-KOct 28, 2026
Adial Pharmaceuticals completed its transformation into Azora Therapeutics, effective October 29…
The company is now a post-merger entity with a new pipeline focus. The large authorized share increase and warrant overhang create significant potential dilution, but the $32M cash runway and…
All ADIL filing & press-release reports (23)
- PRESS-RELEASE reportNov 12, 2026
- 3 reportOct 30, 2026
- 3 reportOct 30, 2026
- 8-K reportOct 28, 2026
- PRESS-RELEASE reportOct 28, 2026
- EFFECT reportOct 27, 2026
- 10-Q/A reportOct 20, 2026
- S-3/A reportOct 20, 2026
- DEFA14A reportOct 16, 2026
- 8-K reportOct 16, 2026
- PRESS-RELEASE reportSep 30, 2026
- DEFA14A reportSep 18, 2026
- 8-K reportSep 18, 2026
- DEFA14A reportSep 16, 2026
- 8-K reportSep 16, 2026
- 8-K reportAug 17, 2026
- PRESS-RELEASE reportAug 17, 2026
- 8-K reportJun 11, 2026
- PRESS-RELEASE reportJun 11, 2026
- 8-K reportMay 11, 2026
- PRESS-RELEASE reportMar 6, 2026
- PRESS-RELEASE reportMar 3, 2026
- 8-K reportFeb 24, 2026